DBV Technologies S.A. (DBVT)
DBVT Stock Price Chart
Explore DBV Technologies S.A. interactive price chart. Choose custom timeframes to analyze DBVT price movements and trends.
DBVT Company Profile
Discover essential business fundamentals and corporate details for DBV Technologies S.A. (DBVT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Oct 2014
Employees
106.00
Website
https://www.dbv-technologies.comCEO
Daniel Tassé
Description
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
DBVT Financial Timeline
Browse a chronological timeline of DBV Technologies S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Oct 2026
EPS estimate is -$0.12, while revenue estimate is $889.42k.
Earnings released on 16 Jul 2026
EPS came in at -$0.49 falling short of the estimated -$0.12 by -307.50%, while revenue for the quarter reached $800.05k , missing expectations by -10.93%.
Earnings released on 30 Apr 2026
EPS came in at -$0.56 falling short of the estimated -$0.14 by -300.00%, while revenue for the quarter reached $1.06m , beating expectations by +11.50%.
Earnings released on 27 Mar 2026
EPS came in at -$1.15 surpassing the estimated -$1.30 by +11.54%, while revenue for the quarter reached $574.60k , missing expectations by -60.47%.
Earnings released on 28 Oct 2025
EPS came in at -$1.20 surpassing the estimated -$1.45 by +17.24%, while revenue for the quarter reached $3.23m , beating expectations by +204.48%.
Earnings released on 29 Jul 2025
EPS came in at -$1.55 falling short of the estimated -$0.21 by -638.10%, while revenue for the quarter reached $1.74m , beating expectations by +129.58%.
Earnings released on 30 Apr 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $906.41k , beating expectations by +81.28%.
Earnings released on 27 Mar 2025
EPS came in at -$1.20 surpassing the estimated -$2.00 by +40.00%, while revenue for the quarter reached $553.10k , beating expectations by +19.52%.
Stock split effective on 29 Nov 2024
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2024
EPS came in at -$0.80 surpassing the estimated -$1.90 by +57.89%, while revenue for the quarter reached $1.18m , beating expectations by +13.01%.
Earnings released on 30 Jul 2024
EPS came in at -$1.70 falling short of the estimated -$1.30 by -30.77%, while revenue for the quarter reached $1.25m , beating expectations by +9.50%.
Stock split effective on 7 Jun 2024
Shares were split 1 : 2 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2024
EPS came in at -$1.40 surpassing the estimated -$2.20 by +36.36%, while revenue for the quarter reached $1.51m , beating expectations by +9.53%.
Earnings released on 7 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.32 by +62.50%, while revenue for the quarter reached $2.44m , missing expectations by -4.61%.
Earnings released on 31 Oct 2023
EPS came in at -$0.18 surpassing the estimated -$0.30 by +40.00%, while revenue for the quarter reached $2.53m , missing expectations by -8.33%.
Earnings released on 31 Jul 2023
EPS came in at -$0.26 matching the estimated -$0.26, while revenue for the quarter reached $2.50m , beating expectations by +25.27%.
Earnings released on 4 May 2023
EPS came in at -$0.22 surpassing the estimated -$0.50 by +56.00%, while revenue for the quarter reached $2.39m , missing expectations by -9.55%.
Earnings released on 2 Mar 2023
EPS came in at -$2.30 matching the estimated -$2.30, while revenue for the quarter reached -$1.40m , missing expectations by -193.34%.
Earnings released on 3 Nov 2022
EPS came in at -$0.18 surpassing the estimated -$0.32 by +43.75%, while revenue for the quarter reached $2.03m , missing expectations by -19.17%.
Earnings released on 1 Aug 2022
EPS came in at -$1.80 falling short of the estimated -$1.70 by -5.88%, while revenue for the quarter reached $1.60m , missing expectations by -6.22%.
Earnings released on 2 May 2022
EPS came in at -$1.50 surpassing the estimated -$4.70 by +68.09%, while revenue for the quarter reached $2.82m , beating expectations by +12.48%.
Earnings released on 3 Mar 2022
EPS came in at -$0.26 surpassing the estimated -$0.64 by +59.38%, while revenue for the quarter reached $2.59m , beating expectations by +7.07%.
Earnings released on 26 Oct 2021
EPS came in at -$2.20 surpassing the estimated -$2.90 by +24.14%, while revenue for the quarter reached $1.54m , missing expectations by -39.94%.
Earnings released on 2 Aug 2021
EPS came in at -$2.80 surpassing the estimated -$6.40 by +56.25%, while revenue for the quarter reached $1.77m .
DBVT Stock Performance
Access detailed DBVT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
